Next Article in Journal
Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media
Next Article in Special Issue
piggyBac-Based Non-Viral In Vivo Gene Delivery Useful for Production of Genetically Modified Animals and Organs
Previous Article in Journal
In Silico Optimization of Fiber-Shaped Aerosols in Inhalation Therapy for Augmented Targeting and Deposition across the Respiratory Tract
Previous Article in Special Issue
Cell Penetrating Peptides, Novel Vectors for Gene Therapy
Review

Gene Therapy in Cancer Treatment: Why Go Nano?

1
UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, Portugal
2
Biomedical Research Centre, Institute of Nutrition and Food Technology, Department of Physiology, Faculty of Pharmacy, University of Granada, Avda. del Conocimiento s/n. 18071 Armilla, Granada, Spain
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(3), 233; https://doi.org/10.3390/pharmaceutics12030233
Received: 29 January 2020 / Revised: 2 March 2020 / Accepted: 3 March 2020 / Published: 5 March 2020
(This article belongs to the Special Issue Non-Viral Gene Delivery Systems)
The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications. View Full-Text
Keywords: gene therapy; gene delivery; tumor microenvironment; nanoparticles; nanomedicine gene therapy; gene delivery; tumor microenvironment; nanoparticles; nanomedicine
Show Figures

Figure 1

MDPI and ACS Style

Roma-Rodrigues, C.; Rivas-García, L.; Baptista, P.V.; Fernandes, A.R. Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics 2020, 12, 233. https://doi.org/10.3390/pharmaceutics12030233

AMA Style

Roma-Rodrigues C, Rivas-García L, Baptista PV, Fernandes AR. Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics. 2020; 12(3):233. https://doi.org/10.3390/pharmaceutics12030233

Chicago/Turabian Style

Roma-Rodrigues, Catarina, Lorenzo Rivas-García, Pedro V. Baptista, and Alexandra R. Fernandes 2020. "Gene Therapy in Cancer Treatment: Why Go Nano?" Pharmaceutics 12, no. 3: 233. https://doi.org/10.3390/pharmaceutics12030233

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop